Single dose was 85 per cent safe against the most serious illness of COVID-19, according to the report
The U.S. is having a third vaccine to stop COVID-19, as the Food and Drug Administration (FDA) cleared a Johnson & Johnson shot on Saturday that operates for only one dose instead of two.
Some were suspicious about the Johnson & Johnson vaccine because the reported effectiveness results were lower than those for the Moderna and Pfizer vaccines. Initially, the vaccine was confirmed to be 66% effective against Covid-19, which paled in contrast to 90-plus per cent for the other two approved vaccines.
“This is really good news,” Dr. Francis Collins, director of the National Institutes of Health (NIH), told The Associated Press Saturday. “The most important thing we can do right now is to get as many shots in as many arms as we can.”
The Johnson & Johnson vaccine is no different in this respect. According to data released by the FDA last week, the effectiveness rate in clinical trials was approximately 72% in the US. But it’s the figure that just informs us of any symptomatic infection, sniffles or short-lived fever.